CDK4 and breast carcinoma: An example of such a practice is the “Treatment of breast cancer” program, which currently permits the use of CDK4/6 inhibitors only in the first- or second-line setting [12], according to the summary of product characteristics for ribociclib that permits ribociclib use only after previous endocrine therapy [15].